Survey of carboplatin dosing strategies in oncology practices

Patrick Blankenship, James Waddell

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives : To identify variations in carboplatin dose calculations at oncology institutions and practices in the southeastern United States. Methods : 500 surveys were mailed to oncology practices in the southeastern United States to assess variations in carboplatin doses. The survey sought to determine assumptions that are made regarding carboplatin calculations and if different carboplatin doses result when participants are given the same data and patient characteristics. Results : The survey had a response rate of 12% (n = 56 of 467). The majority of responses used actual serum creatinine and actual body weight. The Cockcroft-Gault creatinine clearance formula was used most commonly. The doses calculated in the case example of an AUC (area under the curve) 6 dose of carboplatin ranged from 110 to 1,811 mg (mean 987 mg, median 963 mg). We determined a correct dose of 721 mg for the case example. Conclusion : The majority of responses to the case example indicated overdosing of carboplatin. Participants provided inconsistent doses, and their interpretation of the variables in the equations varied. More research is needed, and efforts should be made to have a universal modified Calvert formula with standardized assumptions to achieve consistent dosing across practices.

Original languageEnglish (US)
Pages (from-to)420-422
Number of pages3
JournalJournal of the American Pharmacists Association
Volume53
Issue number4
DOIs
StatePublished - Jan 1 2013

Fingerprint

Oncology
Carboplatin
Southeastern United States
Creatinine
Area Under Curve
Surveys and Questionnaires
Body Weight
Serum
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology (nursing)
  • Pharmacy
  • Pharmacology

Cite this

Survey of carboplatin dosing strategies in oncology practices. / Blankenship, Patrick; Waddell, James.

In: Journal of the American Pharmacists Association, Vol. 53, No. 4, 01.01.2013, p. 420-422.

Research output: Contribution to journalArticle

@article{b2d01b0e870e469d888d79e51e5269c8,
title = "Survey of carboplatin dosing strategies in oncology practices",
abstract = "Objectives : To identify variations in carboplatin dose calculations at oncology institutions and practices in the southeastern United States. Methods : 500 surveys were mailed to oncology practices in the southeastern United States to assess variations in carboplatin doses. The survey sought to determine assumptions that are made regarding carboplatin calculations and if different carboplatin doses result when participants are given the same data and patient characteristics. Results : The survey had a response rate of 12{\%} (n = 56 of 467). The majority of responses used actual serum creatinine and actual body weight. The Cockcroft-Gault creatinine clearance formula was used most commonly. The doses calculated in the case example of an AUC (area under the curve) 6 dose of carboplatin ranged from 110 to 1,811 mg (mean 987 mg, median 963 mg). We determined a correct dose of 721 mg for the case example. Conclusion : The majority of responses to the case example indicated overdosing of carboplatin. Participants provided inconsistent doses, and their interpretation of the variables in the equations varied. More research is needed, and efforts should be made to have a universal modified Calvert formula with standardized assumptions to achieve consistent dosing across practices.",
author = "Patrick Blankenship and James Waddell",
year = "2013",
month = "1",
day = "1",
doi = "10.1331/JAPhA.2013.12053",
language = "English (US)",
volume = "53",
pages = "420--422",
journal = "Journal of the American Pharmacists Association : JAPhA",
issn = "1544-3191",
publisher = "American Pharmacists Association",
number = "4",

}

TY - JOUR

T1 - Survey of carboplatin dosing strategies in oncology practices

AU - Blankenship, Patrick

AU - Waddell, James

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objectives : To identify variations in carboplatin dose calculations at oncology institutions and practices in the southeastern United States. Methods : 500 surveys were mailed to oncology practices in the southeastern United States to assess variations in carboplatin doses. The survey sought to determine assumptions that are made regarding carboplatin calculations and if different carboplatin doses result when participants are given the same data and patient characteristics. Results : The survey had a response rate of 12% (n = 56 of 467). The majority of responses used actual serum creatinine and actual body weight. The Cockcroft-Gault creatinine clearance formula was used most commonly. The doses calculated in the case example of an AUC (area under the curve) 6 dose of carboplatin ranged from 110 to 1,811 mg (mean 987 mg, median 963 mg). We determined a correct dose of 721 mg for the case example. Conclusion : The majority of responses to the case example indicated overdosing of carboplatin. Participants provided inconsistent doses, and their interpretation of the variables in the equations varied. More research is needed, and efforts should be made to have a universal modified Calvert formula with standardized assumptions to achieve consistent dosing across practices.

AB - Objectives : To identify variations in carboplatin dose calculations at oncology institutions and practices in the southeastern United States. Methods : 500 surveys were mailed to oncology practices in the southeastern United States to assess variations in carboplatin doses. The survey sought to determine assumptions that are made regarding carboplatin calculations and if different carboplatin doses result when participants are given the same data and patient characteristics. Results : The survey had a response rate of 12% (n = 56 of 467). The majority of responses used actual serum creatinine and actual body weight. The Cockcroft-Gault creatinine clearance formula was used most commonly. The doses calculated in the case example of an AUC (area under the curve) 6 dose of carboplatin ranged from 110 to 1,811 mg (mean 987 mg, median 963 mg). We determined a correct dose of 721 mg for the case example. Conclusion : The majority of responses to the case example indicated overdosing of carboplatin. Participants provided inconsistent doses, and their interpretation of the variables in the equations varied. More research is needed, and efforts should be made to have a universal modified Calvert formula with standardized assumptions to achieve consistent dosing across practices.

UR - http://www.scopus.com/inward/record.url?scp=84890478403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890478403&partnerID=8YFLogxK

U2 - 10.1331/JAPhA.2013.12053

DO - 10.1331/JAPhA.2013.12053

M3 - Article

VL - 53

SP - 420

EP - 422

JO - Journal of the American Pharmacists Association : JAPhA

JF - Journal of the American Pharmacists Association : JAPhA

SN - 1544-3191

IS - 4

ER -